U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Size, Share & Trends Analysis Report By Type (SPECT, PET), By PET Product (F-18, C-11, Ga-68 PSMA), And Segment Forecasts, 2019 - 2026

Table of Contents

Chapter 1 Methodology and Scope
                   1.1 Research Methodology
                   1.2 Research Scope and Assumptions
                   1.3 Limitation
                   1.4 List of Abbreviations
Chapter 2 Executive Summary
                   2.1 Market Summary
Chapter 3 Market Variables, Trends & Scope
                   3.1 Market Segmentation
Chapter 4 Market Definitions
Chapter 5 Industry Outlook
                   5.1 Market Lineage Outlook
                       5.1.1 Parent Market Outlook
                   5.2 Penetration and Growth Prospect Mapping
                   5.3 Market variable Analysis
                       5.3.1 Rising Incidence Of Prostate Cancer
                       5.3.2 Development Of Novel Radiopharmaceuticals
                       5.3.3 Growing Demand For Accurate Diagnostic Methods
                       5.3.4 Presence Of Reimbursement Policies And Funding Programs
                   5.4 Market Restraint Analysis
                       5.4.1 Stringent Regulations Pertaining To Production, Storage, & Usage
                       5.4.2 High Costs Associated With Diagnostic Procedures
                   5.5 SWOT Analysis; By factor (Political & legal, economic and technological)
                   5.6 Porter’s five forces analysis
                   5.7 Regulatory Scenario
                       5.7.1 U.S.
Chapter 6 Competitive Analysis
                   6.1 Recent Developments & Impact Analysis, By Key Market Participants
                   6.2 Vendor Landscape
                       6.2.1 Key Market Share Analysis, 2018
                   6.3 Private Companies
                       6.3.1 Regional Network Map
Chapter 7 Type Business Analysis
                   7.1 U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Type Movement Analysis
                       7.1.1 SPECT
                           7.1.1.1 SPECT market, 2014 - 2026 (USD Million)
                       7.1.2 PET
                           7.1.2.1 PET market, 2014 - 2026 (USD Million)
Chapter 8 Product Mode Business Analysis
                   8.1 U.S. Prostate Cancer PET Nuclear Medicine Diagnostics Market: Product Movement Analysis
                       8.1.1 F18
                           8.1.1.1 F18 market, 2014 - 2026 (USD Million)
                       8.1.2 C11
                           8.1.2.1 C11 market, 2014 - 2026 (USD Million)
                       8.1.3 GA 68 PSMA
                           8.1.3.1 Ga 68 PSMA market, 2014 - 2026 (USD Million)
Chapter 9 Company Profile
                   9.1 BLUE EARTH DIAGNOSTICS LIMITED.
                       9.1.1 Company overview
                       9.1.2 Product benchmarking
                       9.1.3 Strategic initiatives
                   9.2 PETNET SOLUTIONS INC.
                       9.2.1 Company overview
                       9.2.2 Financial performance
                       9.2.3 Product benchmarking
                       9.2.4 Strategic initiatives
                   9.3 CARDINAL HEALTH
                       9.3.1 Company overview
                       9.3.2 Financial performance
                       9.3.3 Product benchmarking
                   9.4 CURIUM PHARMA
                       9.4.1 Company overview
                           9.4.1.1 Product benchmarking
                           9.4.1.2 Strategic initiatives
                       9.4.2 LANTHEUS MEDICAL IMAGING
                           9.4.2.1 Company overview
                           9.4.2.2 Financial overview
                           9.4.2.3 Product benchmarking
                       9.4.3 ADVANCED ACCELERATOR APPLICATIONS
                           9.4.3.1 Company overview
                           9.4.3.2 Product benchmarking
                           9.4.3.3 Strategic initiatives
                   9.5 JUBILANT PHARMA. LLC (TRIAD ISOTOPES, INC.)
                       9.5.1 Company overview
                       9.5.2 Financial performance
                       9.5.3 Product benchmarking
                       9.5.4 Strategic initiatives
                   9.6 NCM-USA LLC
                       9.6.1 Company overview
                       9.6.2 Product benchmarking
                       9.6.3 PROGENICS PHARMACEUTICALS, INC.
                           9.6.3.1 Company overview
                           9.6.3.2 Financial performance
                           9.6.3.3 Product benchmarking
                           9.6.3.4 Strategic initiatives
                   9.7 TELIX PHARMACEUTICALS LIMITED
                       9.7.1 Company overview
                       9.7.2 Financial performance
                       9.7.3 Product benchmarking
                       9.7.4 Strategic initiatives
                   9.8 IMAGINAB, INC.
                       9.8.1 Company overview
                       9.8.2 Product benchmarking
                       9.8.3 Strategic initiatives
                   9.9 THERAGNOSTICS
                       9.9.1 Company overview
                       9.9.2 Product benchmarking
                       9.9.3 Strategic initiatives
                   9.10 NOVARTIS AG
                       9.10.1 Company overview
                       9.10.2 Product benchmarking
                       9.10.3 Strategic initiatives
                   9.11 LIFE MOLECULAR IMAGING (ALLIANCE MEDICAL MOLECULAR IMAGING)
                       9.11.1 Company overview
                       9.11.2 Product benchmarking
                       9.11.3 Strategic initiatives
                   9.12 ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH
                       9.12.1 Company overview
                       9.12.2 Product benchmarking
                   9.13 ROTOP PHARMAKA GMBH
                       9.13.1 Company overview
                       9.13.2 Product benchmarking
                       9.13.3 Strategic initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 List of key emerging companies /technology disruptors/innovators
Table 3 F-18 pipeline radiopharmaceuticals
Table 4 Ga-68 pipeline radiopharmaceuticals
Table 5 U.S.Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2014 - 2026 (USD Million)
Table 6 U.S.Prostate Cancer PET Nuclear Medicine Diagnostics Market, By Product, 2014 - 2026 (USD Million)

List of Figures

Fig. 1 U.S. prostate cancer nuclear medicine diagnostics market snapshot
Fig. 2 U.S. prostate cancer nuclear medicine diagnostics market segmentation
Fig. 3 Parent market outlook
Fig. 4 Penetration and growth prospect mapping
Fig. 5 U.S. prostate cancer nuclear medicine diagnostics market driver impact
Fig. 6 U.S. prostate cancer (percent of cases by stages )
Fig. 7 U.S. prostate cancer nuclear medicine diagnostics market restraint impact
Fig. 8 SWOT analysis, by factor (political & legal economic and technological)
Fig. 9 Porter’s five forces analysis
Fig. 10 Company market position analysis
Fig. 11 Regional Network Map
Fig. 12 U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Type outlook and key takeaways
Fig. 13 U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Type movement analysis
Fig. 14 SPECT market, 2014 - 2026 (USD Million)
Fig. 15 PET market, 2014 - 2026 (USD Million)
Fig. 16 U.S. Prostate Cancer PET Nuclear Medicine Diagnostics Market: product outlook and key takeaways
Fig. 17 U.S. Prostate Cancer PET Nuclear Medicine Diagnostics Market: Product Movement Analysis
Fig. 18 F18 market, 2014 - 2026 (USD Million)
Fig. 19 C11 market, 2014 - 2026 (USD Million)
Fig. 20 Ga 68 PSMA market, 2014 - 2026 (USD Million)
Fig. 21 Company Profile